Background
The pursuit of successful therapies for pulmonary arterial hypertension (PAH) has been impeded by a lack of small animal models that effectively mimic human disease. Many potential therapies have successfully prevented or reversed pathology and pathophysiology in animal models over the past 50 years (namely, the chronic hypoxia model in mice or rats or the monocrotaline model in rats), but have failed to reverse human PAH (de Jesus Perez, 2016) , indicating that human PAH is distinct in some way from these animal conditions and necessitating the continued pursuit of better models.
Taraseviciene-Stewart et al. (2001) described a new model of PAH in rats using a vascular endothelial growth factor (VEGF) receptor antagonist (Sugen 5416) plus chronic hypoxia (SuHx). Since both human PAH and animal models are characterized by elevated levels of pro-angiogenic VEGF, the mechanism by which Sugen 5416, an anti-angiogenic VEGF receptor antagonist, contributes to PAH is puzzling (Voelkel & Gomez-Arroyo, 2014) . Moreover, exposure to hypoxia is known to cause PAH in humans, but exposure to VEGF receptor antagonism is not obviously representative of any known pathogenic mechanism of human PAH.
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Nevertheless, the rat model of SuHx is widely used because of the advantages of this model over hypoxia alone: higher pulmonary artery pressure and right ventricular hypertrophy (RVH) and development of arteriolar intimal hyperplasia and angioobliterative lesions. These lesions develop over time in normoxia after the SuHx exposure is completed (Abe et al. 2010) and they lead to progressive worsening of right ventricular (RV) systolic pressure and RVH (Oka et al. 2007 ) and development of RV dysfunction (Frump et al. 2015; Lahm et al. 2016) .
Mice are genetically modifiable and less expensive than rats, so naturally several groups attempted the SuHx model in mice. Gomez-Arroyo et al. (2012) reported on their multiple failed attempts, but Ciuclan et al. (2011) ultimately reported a mouse SuHx model in 2011. Since publication, multiple authors have studied PAH therapies and mechanisms in mice using the Ciuclan SuHx procedure, performing pulmonary vascular and cardiac evaluations at the end of the third week of hypoxia (Ciuclan et al. 2013a,b; Liu et al. 2014; Golob et al. 2016; Stevens et al. 2016; Breen et al. 2017; Penumatsa et al. 2017; Suzuki et al. 2018; Boehm et al. 2018) .
Unfortunately, mice exposed to hypoxia or SuHx have a less severe phenotype than rats. The mouse SuHx model leads to higher RV systolic pressures and more RVH than chronic hypoxia alone when evaluated at 3 weeks (Ciuclan et al. 2011; Vitali et al. 2015) , but the mouse SuHx model described by Ciuclan is a poor model of human PAH because (1) it does not lead to progressive intimal hyperplasia and obliterative angiopathy, (2) the pulmonary vascular pathology and RVH revert to normal after return to normoxia, and (3) it does not cause RV failure. These features are essential components of human PAH and must be targeted with new experimental therapies.
Lack of intimal proliferation and angioobliterative lesions
VEGF receptor antagonism by Sugen 5416 is thought to lead to endothelial proliferation and arteriolar occlusion by causing endothelial cell apoptosis, thereby allowing apoptosis-resistant endothelial cells to proliferate. SuHx rats followed for 10 weeks after return to normoxia (13 weeks after the administration of Sugen 5416) have severe progressive arteriopathy that includes concentric neointimal proliferation developing by 5 weeks and occlusive lesions of arterioles that mirrored human PAH plexiform lesions developing by 10 weeks (Abe et al. 2010) . In contrast, pulmonary arteriolar remodelling in the SuHx mouse model is limited to medial hypertrophy at the end of 3 weeks of hypoxia that reverses completely to normoxic baseline by 10 weeks after returning to normoxia (Vitali et al. 2015) . Sporadic obstructed arterioles have been reported in the SuHx mouse, but an extensive search to quantify and characterize these obstructed vessels at 10 weeks after return to normoxia revealed very rare obstructed vessels that had no evidence of concentric medial or intimal proliferation (Vitali et al. 2015) .
This limitation of the mouse SuHx model has impeded mechanistic studies of endothelial changes in PAH. Recently, Suzuki and others studied endothelialto-mesenchymal transition (EMT) in the mouse SuHx model in the hope of better understanding its contribution to intimal proliferation. They found evidence of EMT in the model including identifying EMT endothelial cells by confocal microscopy, but they could not study EMT in intimal proliferative lesions because J Physiol 597.4
there were none to study. They noted the necessity to investigate EMT in a mouse model that is characterized by these lesions such as the prolyl hydroxylase domain-containing enzyme 2 (PHD2)-deficient mouse (Suzuki et al. 2018 ).
Lack of progressive right ventricular dysfunction and failure
Patients with PAH die from RV failure, and indices of RV dysfunction predict death in PAH. The evolution of human RV dysfunction and failure in PAH has a number of different contributory mechanisms including inadequate matching of increases in RV contractility to afterload (reduced Ees/Ea ratio), RV diastolic dysfunction, RV fibrosis, inadequate RV angiogenesis and RV cardiomyocyte metabolic dysfunction, among other mechanisms (van de Veerdonk et al. 2016) . The SuHx rat model has been evaluated for evidence of RV dysfunction and failure by the gold-standard method of pressure-volume catheterization. At the end of 4 weeks of hypoxia there is no significant difference in cardiac function between SuHx rats and normoxic rats, but RV dysfunction develops over 3-10 weeks after return to normoxia, most notably in male and ovariectomized female rats that have been strenuously exercised (Frump et al. 2015; Lahm et al. 2016 ). The SuHx 3-week mouse model reported by Ciuclan et al . is a poor model of RV dysfunction and failure in PAH. Wang and colleagues used pressure-volume catheterization to evaluate RV function in male mice after 14, 21, or 28 days of hypoxia plus weekly Sugen 5416 injections and found no significant difference in RV function (Wang et al. 2013) . The same authors recently reported evidence of RV dysfunction with impaired preload-independent contractility by modifying the Ciuclan procedure to continue hypoxia and weekly Sugen 5416 injections for 8 weeks (Wang et al. 2018) . Unfortunately, even after extending the hypoxia and Sugen 5416 exposure of the Ciuclan model by 2.67 times, RV cardiac output was preserved and the authors noted that there was no evidence of RV failure (Wang et al. 2018) .
Reversibility on return to normoxia
Human PAH is characterized by progressive early medial and adventitial thickening followed by neointimal proliferation and eventual vascular occlusion leading to 'pruning' of the pulmonary arterial vessels (Shimoda & Laurie, 2013) . No therapy has been found to reverse this process. The rat SuHx model is characterized by progressive intimal proliferation and vascular obliteration after removal from hypoxia; the right ventricular systolic pressure (RVSP) similarly increases over time and the increase is correlated with the number of occluded pulmonary arterioles (Oka et al. 2007) . In contrast, the mouse SuHx vascular pathology is characterized by medial hypertrophy which reverses to normoxic level after return to normoxia and RVH similarly improves over time (Vitali et al. 2015) . In order to test potential therapies for their ability to reverse PAH in humans, an animal model that does not reverse spontaneously is essential.
Conclusions and future directions
The findings of higher RVSP and RVH in the Ciuclan three week SuHx mouse model when compared to chronic hypoxia alone do not indicate that the model better represents human PAH. Neither model leads to RV dysfunction or failure and neither causes progressive pulmonary arteriopathy. Fortunately, the quest for better mouse models of PAH has continued and several recently reported genetically modified mouse models have spontaneous PAH (Dai & Zhao, 2017) or more severe PAH when combined with SuHx . For example, mice with Tie2-Cre-mediated disruption of the gene encoding PHD2 in endothelial and haematopoetic cells has spontaneous, severe, progressive PH with vascular lesions that mirror those in human PAH (Dai et al. 2016) . All of the small animal models are valuable in studies of the underlying mechanisms of PAH, but human PAH is a fatal condition and care must be taken to avoid expending unnecessary time and resources testing promising therapies in models that do not cause the most deadly features of the human disease.
Call for comments
Readers are invited to give their views on this and the accompanying CrossTalk articles in this issue by submitting a brief (250 word) comment. Comments may be submitted up to 6 weeks after publication of the article, at which point the discussion will close and the CrossTalk authors will be invited to submit a 'LastWord' . Please email your comment, including a title and a declaration of interest, to jphysiol@physoc.org. Comments will be moderated and accepted comments will be published online only as 'supporting information' to the original debate articles once discussion has closed.
